RxDoctor Payments Data

Marla Dixon, PA

Medical · Gainesville, GANPI 1598814469

Payments from drug & device makers

$7,365in general payments, 2019–2025

Across 369 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Ardelyx, Inc.$927
  • Johnson & Johnson$641
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$561
  • Takeda Pharmaceuticals U.S.A., Inc.$554
  • Sanofi$255
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$7,26799%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,365 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$46,350
Medicare patients
448
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin19$58,974
LinzessLinaclotide43$58,580
IbsrelaTenapanor Hcl19$51,023
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates286$18,985
Pantoprazole Sodium345$5,096
Dicyclomine Hcl67$2,720
Sucralfate16$2,606
Famotidine181$2,514
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag16$1,881
Ondansetron OdtOndansetron306$1,676
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C12$1,674
SuprepSodium, Potassium,mag Sulfates12$1,344
Esomeprazole Magnesium19$1,080
Omeprazole62$917
Colestipol Hcl13$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$561$60,64831 claims
AbbVieLinzess$2,290$58,58043 claims
Ardelyx, Inc.Ibsrela$927$51,02319 claims
Braintree Laboratories, Inc.Suflave$29$1,88116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.

Other medical in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →